<DOC>
	<DOCNO>NCT00301288</DOCNO>
	<brief_summary>Patients aggressive Non−Hodgkin−lymphoma treat first diagnosis chemotherapy alone combine chemo-radiotherapy achieve high response rate . However , patient relapse lymphoma still poor prognosis . High dose chemotherapy ( HDCT ) follow autologous stem cell transplantation ( ASCT ) treatment choice patient . An ASCT allow patient receive much high dos chemotherapy usual , improve chance cure disease . The high−dose chemotherapy destroy cell patient bone marrow patient cell either bone marrow peripheral blood use rescue patient intensive treatment . High−dose chemotherapy autologous stem cell ( either bone marrow peripheral blood ) transplantation use treatment Intermediate/High grade NHL poor risk disease second remission Royal Marsden Hospital . The purpose present analysis determine independent prognostic factor correlate long−term outcome patient NHL receive ASCT January 1991 June 2005 . Accrual eligible patient currently follow−up perform clinic time next appointment . All patient accrue give informed consent participate study retrospective case note review , discussion study investigator receive study information sheet . The result analysis publish peer−reviewed medical journal . This include patient treat royal Marsden Hospital .</brief_summary>
	<brief_title>A Retrospective Study Toxicity Outcome High Dose Chemotherapy With Autologous Stem Cell Transplant Patients With Non-Hodgkin Lymphoma ( NHL ) .</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>) Age 18 b ) Patients NonHodgkin 's Lymphoma receive autologous stem cell transplant past . c ) Informed write consent ) Medical psychiatric condition compromise patient 's ability give inform consent b ) HIV positive AIDS relate lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>